Switch theme
Sign up to access all valuation multiples
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
1864
12.1K+
LTM Revenue $2.5B
LTM EBITDA $524M
$4.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gerresheimer has a last 12-month revenue (LTM) of $2.5B and a last 12-month EBITDA of $524M.
In the most recent fiscal year, Gerresheimer achieved revenue of $2.3B and an EBITDA of $456M.
Gerresheimer expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gerresheimer valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | XXX | $2.3B | XXX | XXX | XXX |
| Gross Profit | $770M | XXX | $683M | XXX | XXX | XXX |
| Gross Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $524M | XXX | $456M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $271M | XXX | $262M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $139M | XXX | $123M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Gerresheimer's stock price is EUR 63 (or $71).
Gerresheimer has current market cap of EUR 2.2B (or $2.5B), and EV of EUR 4.2B (or $4.7B).
See Gerresheimer trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7B | $2.5B | XXX | XXX | XXX | XXX | $5.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Gerresheimer has market cap of $2.5B and EV of $4.7B.
Gerresheimer's trades at 2.0x EV/Revenue multiple, and 10.0x EV/EBITDA.
Equity research analysts estimate Gerresheimer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gerresheimer has a P/E ratio of 17.6x.
See valuation multiples for Gerresheimer and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $4.7B | XXX | $4.7B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 8.9x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBIT | 17.2x | XXX | 17.5x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.6x | XXX | 19.5x | XXX | XXX | XXX |
| EV/FCF | -30.4x | XXX | -31.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGerresheimer's last 12 month revenue growth is 14%
Gerresheimer's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $35K for the same period.
Gerresheimer's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gerresheimer's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gerresheimer and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | 35% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gerresheimer acquired XXX companies to date.
Last acquisition by Gerresheimer was XXXXXXXX, XXXXX XXXXX XXXXXX . Gerresheimer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gerresheimer founded? | Gerresheimer was founded in 1864. |
| Where is Gerresheimer headquartered? | Gerresheimer is headquartered in Germany. |
| How many employees does Gerresheimer have? | As of today, Gerresheimer has 12.1K+ employees. |
| Is Gerresheimer publicy listed? | Yes, Gerresheimer is a public company listed on ETR. |
| What is the stock symbol of Gerresheimer? | Gerresheimer trades under GXI ticker. |
| When did Gerresheimer go public? | Gerresheimer went public in 2007. |
| Who are competitors of Gerresheimer? | Similar companies to Gerresheimer include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Gerresheimer? | Gerresheimer's current market cap is $2.5B |
| What is the current revenue of Gerresheimer? | Gerresheimer's last 12 months revenue is $2.5B. |
| What is the current revenue growth of Gerresheimer? | Gerresheimer revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Gerresheimer? | Current revenue multiple of Gerresheimer is 1.8x. |
| Is Gerresheimer profitable? | Yes, Gerresheimer is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gerresheimer? | Gerresheimer's last 12 months EBITDA is $524M. |
| What is Gerresheimer's EBITDA margin? | Gerresheimer's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Gerresheimer? | Current EBITDA multiple of Gerresheimer is 8.9x. |
| What is the current FCF of Gerresheimer? | Gerresheimer's last 12 months FCF is -$154M. |
| What is Gerresheimer's FCF margin? | Gerresheimer's last 12 months FCF margin is -6%. |
| What is the current EV/FCF multiple of Gerresheimer? | Current FCF multiple of Gerresheimer is -30.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
